Equities researchers at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP stock opened at $3.81 on Friday. Titan Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $14.80. The stock’s fifty day moving average is $3.49 and its two-hundred day moving average is $4.44.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Calculate Stock Profit
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Invest in Small Cap Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
